Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2021 - 06 - 11 save search
Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device
Published: 2021-06-11 (Crawled : 23:00) - biospace.com/
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: -0.43%
H: 2.27%
C: -0.36%
test device merge authorized emergency use authorization
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Published: 2021-06-11 (Crawled : 18:17) - fda.gov
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
fda fda approval cancer
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.5%
H: 0.33%
C: -3.67%
approval fda granted cancer prostate cancer grant
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $132.73 0.22% 0.0% 1.3M
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.12%
approval fda fda approval nivolumab
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
Published: 2021-06-11 (Crawled : 17:07) - fda.gov
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.79%
H: 1.13%
C: -1.29%
fda approval fda approval
DAVIDsTEA Creditors Approve CCAA Plan of Arrangement
Published: 2021-06-11 (Crawled : 16:00) - globenewswire.com
DTEA | $0.52 -9.64% 190K
|
Consumer Non-Durables
|
| O: 0.19%
H: 12.0%
C: -2.1%
approval
FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Published: 2021-06-11 (Crawled : 14:04) - fda.gov
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
fda granted approval leukemia myeloid leukemia grant acute myeloid leukemia
FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
Published: 2021-06-11 (Crawled : 13:55) - fda.gov
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.5%
H: 0.33%
C: -3.67%
cancer test fda fda approval diagnostic biomarkers
FDA approves selinexor for refractory or relapsed multiple myeloma
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.61%
H: 0.09%
C: -3.73%
fda approval fda approval
FDA approves pralsetinib for RET-altered thyroid cancers
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: 1.41%
H: 2.24%
C: 1.88%
cancer fda approval fda approval
FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Published: 2021-06-11 (Crawled : 13:47) - fda.gov
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
|
| O: 0.05%
H: 1.54%
C: -3.36%
risk fda granted approval grant
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
Published: 2021-06-11 (Crawled : 13:15) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 10.07%
H: 0.22%
C: -3.79%
phase 2 approval
FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
Published: 2021-06-11 (Crawled : 13:10) - fda.gov
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.52%
H: 0.18%
C: -0.7%
cancer fda fda approval
FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Published: 2021-06-11 (Crawled : 13:02) - fda.gov
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -0.14%
H: 0.42%
C: 0.14%
fda fda approval cell carcinoma
FDA approves isatuximab-irfc for multiple myeloma
Published: 2021-06-11 (Crawled : 12:53) - fda.gov
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
fda approval fda approval
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
Published: 2021-06-11 (Crawled : 12:43) - fda.gov
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.18%
H: 2.19%
C: 0.14%
fda granted approval grant t-cell
FDA approves nivolumab for resected esophageal or GEJ cancer
Published: 2021-06-11 (Crawled : 12:24) - fda.gov
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.74%
H: 0.07%
C: -0.81%
cancer fda approval fda approval nivolumab
Aetna Better Health Premier Plan MMAI approved to expand statewide to serve dual eligible Medicare-Medicaid customers across Illinois
Published: 2021-06-11 (Crawled : 12:15) - prnewswire.com
CVS | $69.75 1.49% 0.13% 7.8M
|
Retail Trade
|
| O: 0.41%
H: 0.33%
C: -0.44%
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.18%
H: 2.19%
C: 0.14%
approval
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
treatment potential anemia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.